Charts Genome & Company

Equities

End-of-day quote Korea S.E. Other stock markets 18:00:00 2024-05-09 EDT			5-day change	1st Jan Change
7,180 ^KRW	0.00%		+4.82%	-42.51%

01-24	Genome & Company Announces Positive Topline Results from Phase 2 Clinical Trial of Combination of GEN-001 and Bavencio®? for the Treatment of Gastric Cancer Poster Presented at ASCO GI	CI
2023	Genome & Company Announces Positive Results from Interim Analysis of Gen-001 Plus Avelumab (Bavencio®?) Phase II Trial	CI

ProRealTime Chart